Abstract
The use of amobarbital sodium (amytal sodium R) as a diagnostic test for brain disease is described. In 57 of 88 patients with proven brain disease, who on clinical examination showed no disturbances in behavior, the intravenous administration of the drug produced patterns of disorientation for time, place, and person and denial of illness. These changes were not obtained in any of 50 control patients. The applicability of the procedure to the study of alterations in brain function caused by structural, iatrogenic, metabolic, and toxic agents is discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
